Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Sales and Divestitures (2023 - 2024)

Maxcyte (MXCT) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $418260.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures rose 44.95% to $418260.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $418260.0, a 44.95% increase, with the full-year FY2024 number at $418260.0, up 44.95% from a year prior.
  • Gains from Sales and Divestitures was $418260.0 for Q4 2024 at Maxcyte, up from $288550.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $418260.0 in Q4 2024 to a low of $288550.0 in Q4 2023.